Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Maybe you can also pay attention to our smart microplate reader
ELISA Kit for Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9)
FH3; HCHOLA3; NARC1; Hypercholesterolemia,Autosomal Dominant 3; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
- Product No.AEE189Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample Typeserum, plasma and other biological fluids
- Test MethodIndirect ELISA
- Assay Length2h, 30min
- Detection Range1.56-100ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.57ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$
US$
US$
US$
US$
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9).
No significant cross-reactivity or interference between Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 95-102 | 99 |
| EDTA plasma(n=5) | 84-98 | 93 |
| heparin plasma(n=5) | 95-102 | 99 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (Anti-PCSK9) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-91% | 93-101% | 82-91% | 78-90% |
| EDTA plasma(n=5) | 79-105% | 89-103% | 93-102% | 85-102% |
| heparin plasma(n=5) | 79-91% | 89-97% | 80-91% | 80-91% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Biological Trace Element Research | Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers pubmed:28409410 |
| BASIC RESEARCH IN CARDIOLOGY | Autocrine effects of PCSK9 on cardiomyocytes Pubmed: 33169229 |
| J Transl Med | Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555 |
| Metabolism | MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice 33775647 |
| Eur Rev Med Pharmacol Sci | Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders 34533801 |
| Clin Exp Hypertens | Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease Pubmed:35502687 |